212 related articles for article (PubMed ID: 33719007)
1. Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters, possible adverse and toxic effects.
Rendic SP
Arch Toxicol; 2021 May; 95(5):1535-1546. PubMed ID: 33719007
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms in MDR1, CYP3A4 and CYP3A5 genes in a Ghanaian population: a plausible explanation for altered metabolism of ivermectin in humans?
Kudzi W; Dodoo AN; Mills JJ
BMC Med Genet; 2010 Jul; 11():111. PubMed ID: 20630055
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist.
Younis I; Weber E; Nelson C; Kirby BJ; Shen G; Xiao D; Watkins TR; Othman AA
Clin Pharmacokinet; 2023 Apr; 62(4):609-621. PubMed ID: 36906733
[TBL] [Abstract][Full Text] [Related]
4. Islatravir Is Not Expected to Be a Victim or Perpetrator of Drug-Drug Interactions via Major Drug-Metabolizing Enzymes or Transporters.
Bleasby K; Houle R; Hafey M; Lin M; Guo J; Lu B; Sanchez RI; Fillgrove KL
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452431
[TBL] [Abstract][Full Text] [Related]
5. In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor.
Zhang H; Ou YC; Su D; Wang F; Wang L; Sahasranaman S; Tang Z
Pharmacol Res Perspect; 2021 Dec; 9(6):e00870. PubMed ID: 34664792
[TBL] [Abstract][Full Text] [Related]
6. No evidence for interactions of dimethylfumarate (DMF) and its main metabolite monomethylfumarate (MMF) with human cytochrome P450 (CYP) enzymes and the P-glycoprotein (P-gp) drug transporter.
Aubets J; Jansat JM; Salva M; Birks VM; Cole RJ; Lewis J; Pitcher A; Hall M
Pharmacol Res Perspect; 2019 Dec; 7(6):e00540. PubMed ID: 31832203
[TBL] [Abstract][Full Text] [Related]
7. Identification of the metabolites of ivermectin in humans.
Tipthara P; Kobylinski KC; Godejohann M; Hanboonkunupakarn B; Roth A; Adams JH; White NJ; Jittamala P; Day NPJ; Tarning J
Pharmacol Res Perspect; 2021 Feb; 9(1):e00712. PubMed ID: 33497030
[TBL] [Abstract][Full Text] [Related]
8. Formation of potentially toxic metabolites of drugs in reactions catalyzed by human drug-metabolizing enzymes.
Rendic SP; Guengerich FP
Arch Toxicol; 2024 Jun; 98(6):1581-1628. PubMed ID: 38520539
[TBL] [Abstract][Full Text] [Related]
9. Effect of P-glycoprotein (P-gp) Inducers on Exposure of P-gp Substrates: Review of Clinical Drug-Drug Interaction Studies.
Elmeliegy M; Vourvahis M; Guo C; Wang DD
Clin Pharmacokinet; 2020 Jun; 59(6):699-714. PubMed ID: 32052379
[TBL] [Abstract][Full Text] [Related]
10. Estimation of the binding modes with important human cytochrome P450 enzymes, drug interaction potential, pharmacokinetics, and hepatotoxicity of ginger components using molecular docking, computational, and pharmacokinetic modeling studies.
Qiu JX; Zhou ZW; He ZX; Zhang X; Zhou SF; Zhu S
Drug Des Devel Ther; 2015; 9():841-66. PubMed ID: 25733806
[TBL] [Abstract][Full Text] [Related]
11. Extracellular Vesicles as Surrogates for the Regulation of the Drug Transporters ABCC2 (MRP2) and ABCG2 (BCRP).
Rigalli JP; Gagliardi A; Diester K; Bajraktari-Sylejmani G; Blank A; Burhenne J; Lenard A; Werntz L; Huppertz A; Münch L; Wendt JM; Sauter M; Haefeli WE; Weiss J
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612927
[TBL] [Abstract][Full Text] [Related]
12. Drugs That Interact With Colchicine Via Inhibition of Cytochrome P450 3A4 and P-Glycoprotein: A Signal Detection Analysis Using a Database of Spontaneously Reported Adverse Events (FAERS).
Gómez-Lumbreras A; Boyce RD; Villa-Zapata L; Tan MS; Hansten PD; Horn J; Malone DC
Ann Pharmacother; 2023 Oct; 57(10):1137-1146. PubMed ID: 36688283
[TBL] [Abstract][Full Text] [Related]
13. Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters.
Matthaei J; Tzvetkov MV; Gal V; Sachse-Seeboth C; Sehrt D; Hjelmborg JB; Hofmann U; Schwab M; Kerb R; Brockmöller J
Genome Med; 2016 Nov; 8(1):119. PubMed ID: 27825374
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the Herb-Drug Interaction (HDI) Potential of
Husain I; Dale OR; Idrisi M; Gurley BJ; Avula B; Katragunta K; Ali Z; Chittiboyina A; Noonan G; Khan IA; Khan SI
J Agric Food Chem; 2023 May; 71(19):7521-7534. PubMed ID: 37134183
[TBL] [Abstract][Full Text] [Related]
15. Cocaine regulates antiretroviral therapy CNS access through pregnane-x receptor-mediated drug transporter and metabolizing enzyme modulation at the blood brain barrier.
Colón Ortiz R; Knerler S; Fridman LB; Mercado A; Price AS; Rosado-Franco JJ; Wilkins H; Flores BR; Orsburn BC; Williams DW
Fluids Barriers CNS; 2024 Jan; 21(1):5. PubMed ID: 38200564
[TBL] [Abstract][Full Text] [Related]
16. Role of Cytochrome P450 2C9 in COVID-19 Treatment: Current Status and Future Directions.
Lim SYM; Al Bishtawi B; Lim W
Eur J Drug Metab Pharmacokinet; 2023 May; 48(3):221-240. PubMed ID: 37093458
[TBL] [Abstract][Full Text] [Related]
17. Role of the Abcg2 Transporter in Secretion into Milk of the Anthelmintic Clorsulon: Interaction with Ivermectin.
Blanco-Paniagua E; Álvarez-Fernández L; Rodríguez-Alonso A; Millán-Garcia A; Álvarez AI; Merino G
Antimicrob Agents Chemother; 2023 May; 67(5):e0009523. PubMed ID: 37078871
[TBL] [Abstract][Full Text] [Related]
18. Tazemetostat synergistically combats multidrug resistance by the unique triple inhibition of ABCB1, ABCC1, and ABCG2 efflux transporters in vitro and ex vivo.
Budagaga Y; Sabet Z; Zhang Y; Novotná E; Hanke I; Rozkoš T; Hofman J
Biochem Pharmacol; 2023 Oct; 216():115769. PubMed ID: 37634597
[TBL] [Abstract][Full Text] [Related]
19. Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data.
Isoherranen N; Lutz JD; Chung SP; Hachad H; Levy RH; Ragueneau-Majlessi I
Chem Res Toxicol; 2012 Nov; 25(11):2285-300. PubMed ID: 22823924
[TBL] [Abstract][Full Text] [Related]
20. Dietary gallic acid as an antioxidant: A review of its food industry applications, health benefits, bioavailability, nano-delivery systems, and drug interactions.
Xiang Z; Guan H; Zhao X; Xie Q; Xie Z; Cai F; Dang R; Li M; Wang C
Food Res Int; 2024 Mar; 180():114068. PubMed ID: 38395544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
